CJC-1295 / Ipamorelin (blend discussion)

CJC/IPA is a two-peptide pairing people discuss for sleep, training recovery and body composition. Here it usually means short-acting CJC no DAC (Mod GRF 1-29) plus ipamorelin. Reports include better rest, no clear change, restless nights and troublesome fatigue; the blend's benefits and long-term safety are not established by those accounts.

Two peptides that prompt growth-hormone release. The no-DAC CJC component, usually called Mod GRF 1-29, acts through the growth-hormone-releasing-hormone pathway; ipamorelin acts through the ghrelin-receptor pathway. Community shorthand calls them an amplifier and trigger. This is stimulation of the body's own release, rather than injected growth hormone.

No DAC and with DAC are different forms. The DAC modification allows CJC to bind to albumin, a blood protein, prolonging its exposure. This article's paired amounts concern no-DAC discussion. A label saying only CJC-1295 leaves an important identity question unresolved; the long-acting DAC study does not validate the daily blend. Ipamorelin End of week Three, page 3 (Community discussion · Accessed 2026-09-30)

Source context — Ipamorelin End of week Three, page 3: Reported blend micrograms do not clearly distinguish total from each component, so not used as numerical dose evidence. DAC/no-DAC and alternative products vary; no prevalence inferred.

Better sleep can be the first noticeable change. One cutting-phase author described deeper sleep and fewer awakenings after almost a week, without noticeable training benefit yet. Another described better sleep, skin and slightly faster lifting recovery by week three, but judged the differences small. CJC-1295+Ipamorelin experience (Community discussion · Accessed 2026-09-30) · Increased sleepiness and vivid dreams on week 3 (Community discussion · Accessed 2026-09-30)

Minutes for a flush; days or weeks for sleep reports. An ExcelMale user described flushing and heart pounding within about one minute, lasting a few minutes: an acute reaction. One cutting-phase author noticed sleep change after almost a week; a six-week account had no obvious sleep change. Ipamorelin and CJC-1295 (no dac) Plan (Community discussion · Accessed 2026-09-30) · CJC-1295+Ipamorelin experience (Community discussion · Accessed 2026-09-30) · Six weeks, IGF-1 barely increased: underdosed, fake or expected? (Community discussion · Accessed 2026-09-30)

Vivid dreams can coexist with poor rest. A 100/200 CJC/IPA account described vivid dreams but less satisfactory bedtime sleep. Another became sleepy enough during week three to lose daytime motivation. Dream intensity is a reported feeling, not proof of restorative sleep. Cjc 1295 ipamorelin dosages and protocols (Community discussion · Accessed 2026-09-30) · Increased sleepiness and vivid dreams on week 3 (Community discussion · Accessed 2026-09-30)

Recovery and physique claims unfold against other changes. A week-five commenter described soreness shrinking from two days to one. Older discussions include joint comfort, fuller-looking skin and lean-mass support during calorie cuts. Training, diet, TRT, other peptides and fluid changes complicate attributing a result to this pair. CJC-1295+Ipamorelin experience (Community discussion · Accessed 2026-09-30)

Source context — CJC-1295+Ipamorelin experience: Author discloses AI translation/editing. Same text appeared in a PepAudit search lead and is not counted twice. Subreddit promotes an external guide; first-person authenticity, DAC status of OP and other stacks unverified. Route-switch anecdote is not a recommendation.

Source context — Increased sleepiness and vivid dreams on week 3: OP has inconsistent week numbering and no objective measurements. Commenter's product details unverified; 'adrenal fatigue' is their interpretation and is not accepted as diagnosis. Cross-post 1ecwsre is the same story, not independent evidence.

Source context — Ipamorelin and CJC-1295 (no dac) Plan: Thread opening includes a polished protocol summary; treated as editorial community synthesis, not original human evidence. Concurrent TRT, diet and supplements confound outcomes. Reaction attribution uncertain. No purchase or mixing instructions reproduced.

Source context — Six weeks, IGF-1 barely increased: underdosed, fake or expected?: Uses 'subject' wording under no-human-use rules; identity/species not independently verified. No lab document reviewed. Small change is neither proven nonresponse nor evidence of a fake vial. Moderator-removed and hidden replies not inspected.

Source context — Cjc 1295 ipamorelin dosages and protocols: OP's final daily-total question switches mcg to mg, and another comment also has a mg typo. Those malformed totals are not reproduced. DAC status and route are not established for every reply; casual sleep physiology and instructions are not adopted.

100 mcg CJC no DAC + 100 mcg ipamorelin per administration. The preserved equal-pair chart is also reported once nightly in an opened six-week lab account. The older paired bands are 100–200 mcg CJC (some charts reach 300) and 100–300 mcg ipamorelin per injection; they are reported practice, not validated dose ranges. Six weeks, IGF-1 barely increased: underdosed, fake or expected? (Community discussion · Accessed 2026-09-30)

Unequal pairs: 100 mcg CJC + 200–300 mcg ipamorelin. An opened account used 100/200 once daily, then twice daily; another reported 100/200 three times daily. The latter totals 300 mcg CJC + 600 mcg ipamorelin per day. Other logs include 150/150 twice daily and 200/200 nightly. These are competing patterns, not escalation steps. Cjc 1295 ipamorelin dosages and protocols (Community discussion · Accessed 2026-09-30) · Sleep issues after skipping a single dose of Ipamorelin + CJC-1295 (Community discussion · Accessed 2026-09-30) · CJC-1295+Ipamorelin experience (Community discussion · Accessed 2026-09-30)

Premixed 1:1 charts: 200–500 mcg combined per injection. The older charts include 5 mg + 5 mg and 10 mg + 10 mg vials. If the stated 1:1 ratio is accurate, 300 mcg total means 150 mcg of each; 200 mcg of each means 400 mcg total. Syringe units alone do not identify a mass dose.

Frequency and saturation claims are disputed. Bedtime-only, morning-plus-night and two-to-three injections daily appear in older charts, reaching about 0.6–1.5+ mg combined daily. Some charts claim benefits plateau at 100 mcg (sometimes expressed as 1 mcg/kg); others favor larger ipamorelin amounts. Neither claim establishes an optimal human blend dose. DAC talk of 1–2 mg weekly belongs to a different form.

Source context — Six weeks, IGF-1 barely increased: underdosed, fake or expected?: Uses 'subject' wording under no-human-use rules; identity/species not independently verified. No lab document reviewed. Small change is neither proven nonresponse nor evidence of a fake vial. Moderator-removed and hidden replies not inspected.

Source context — Cjc 1295 ipamorelin dosages and protocols: OP's final daily-total question switches mcg to mg, and another comment also has a mg typo. Those malformed totals are not reproduced. DAC status and route are not established for every reply; casual sleep physiology and instructions are not adopted.

Source context — Sleep issues after skipping a single dose of Ipamorelin + CJC-1295: Separate users, amounts and products; self-reports without sleep or peptide measurements. Missing dose does not establish dependence. Hidden replies not inspected.

Source context — CJC-1295+Ipamorelin experience: Author discloses AI translation/editing. Same text appeared in a PepAudit search lead and is not counted twice. Subreddit promotes an external guide; first-person authenticity, DAC status of OP and other stacks unverified. Route-switch anecdote is not a recommendation.

Minutes for a flush; days or weeks for sleep reports. An ExcelMale user described flushing and heart pounding within about one minute, lasting a few minutes: an acute reaction. One cutting-phase author noticed sleep change after almost a week; a six-week account had no obvious sleep change. Ipamorelin and CJC-1295 (no dac) Plan (Community discussion · Accessed 2026-09-30) · CJC-1295+Ipamorelin experience (Community discussion · Accessed 2026-09-30) · Six weeks, IGF-1 barely increased: underdosed, fake or expected? (Community discussion · Accessed 2026-09-30)

No dependable single-injection benefit window. One evening user reported only 1–2 hours of sleep after missing a dose; a separate 100/200 three-times-daily user still slept well on Friday/Saturday off-nights. These contrasting accounts do not establish dependence, peptide persistence or a predictable rebound. Sleep issues after skipping a single dose of Ipamorelin + CJC-1295 (Community discussion · Accessed 2026-09-30)

Effects during a course can change. A commenter reported good sleep in weeks one–two, increasing fatigue in week three and worse sleep by week five; their racing heart reportedly settled a week or two after stopping. Older accounts describe sleep drifting toward baseline over days–weeks. Symptom persistence is not clearance time. Increased sleepiness and vivid dreams on week 3 (Community discussion · Accessed 2026-09-30)

No-DAC CJC: about 30 minutes is the circulated estimate. An AnabolicMinds reply repeats it while correcting a multi-day mix-up. Older guides also circulate 1–2 hours. Neither figure is a measured human SubQ-blend value in these sources. Half-life means a measured amount falling by half, not the length of better sleep. Peptide cycle advice (Community discussion · Accessed 2026-09-30)

Ipamorelin: about 2 hours is repeated in forums. Its traceable origin is a healthy-men intravenous-infusion study, rather than a SubQ blend measurement. The pair has no single established half-life: averaging its components, or borrowing the DAC form's multi-day kinetics, would obscure the actual products. Peptide cycle advice (Community discussion · Accessed 2026-09-30)

Ipamorelin alone, intravenous: about 2 hours. Gobburu's 1999 healthy-men study used 15-minute IV infusions. It measured a terminal half-life near two hours and a GH peak around 0.67 hours. Those measurements do not establish SubQ-blend kinetics, sleep benefits or the community amount charts. Gobburu et al. 1999: human volunteer ipamorelin PK/PD (Official context · Accessed 2026-09-30)

Source context — Ipamorelin and CJC-1295 (no dac) Plan: Thread opening includes a polished protocol summary; treated as editorial community synthesis, not original human evidence. Concurrent TRT, diet and supplements confound outcomes. Reaction attribution uncertain. No purchase or mixing instructions reproduced.

Source context — CJC-1295+Ipamorelin experience: Author discloses AI translation/editing. Same text appeared in a PepAudit search lead and is not counted twice. Subreddit promotes an external guide; first-person authenticity, DAC status of OP and other stacks unverified. Route-switch anecdote is not a recommendation.

Source context — Six weeks, IGF-1 barely increased: underdosed, fake or expected?: Uses 'subject' wording under no-human-use rules; identity/species not independently verified. No lab document reviewed. Small change is neither proven nonresponse nor evidence of a fake vial. Moderator-removed and hidden replies not inspected.

Source context — Sleep issues after skipping a single dose of Ipamorelin + CJC-1295: Separate users, amounts and products; self-reports without sleep or peptide measurements. Missing dose does not establish dependence. Hidden replies not inspected.

Source context — Increased sleepiness and vivid dreams on week 3: OP has inconsistent week numbering and no objective measurements. Commenter's product details unverified; 'adrenal fatigue' is their interpretation and is not accepted as diagnosis. Cross-post 1ecwsre is the same story, not independent evidence.

Source context — Peptide cycle advice: Proposal/opinion, not results from a three-compound cycle. No original kinetic citations in thread. Vendor questions not reproduced; repeated quoted reply is not independent evidence.

Source context — Gobburu et al. 1999: human volunteer ipamorelin PK/PD: Abstract only, not full text. IV monotherapy cannot validate SubQ paired-dose charts, food windows or blend outcomes.

8–12 weeks on, about 4 weeks off is an older template. Other preserved calendars are three months on/one off, 1–3 months on/2–3 off, and equal eight-week on/off blocks. A recent author actually reported two months on/one off, then severe reactions on restarting. None establishes an effective or safe cycle. My experience with cjc/ipamorelin (Personal report · Accessed 2026-09-30)

Five days on/two off appears in actual reports. The 150 mcg CJC + 200 mcg ipamorelin week-three account used that pattern. Older four-on/three-off and continuous multi-month patterns also exist. Cost, injection burden, checking off-day benefits and theoretical receptor rest motivate breaks; a reliable receptor-reset interval is unproven. Increased sleepiness and vivid dreams on week 3 (Community discussion · Accessed 2026-09-30)

Source context — My experience with cjc/ipamorelin: DAC form, component split, purity and clinical diagnosis not established. Amounts therefore omitted from no-DAC dose bands. Self-reported fainting cannot establish mechanism, frequency or confirmed anaphylaxis.

Source context — Increased sleepiness and vivid dreams on week 3: OP has inconsistent week numbering and no objective measurements. Commenter's product details unverified; 'adrenal fatigue' is their interpretation and is not accepted as diagnosis. Cross-post 1ecwsre is the same story, not independent evidence.

MK-677 (Ibutamoren): Compared or stacked for oral 24h GH-axis coverage + sleep; adds appetite, water, and fasting-glucose confound. Some prefer inject-only secretagogues during cuts; others run low-dose MK with bedtime CJC/IPA. Redundant GHS load is a common caution. [community]

GHRH swaps: Sermorelin or tesamorelin may replace CJC as the GHRH leg; Ipamorelin often stays as the GHS leg (Sermorelin+IPA and Tesa+IPA are named alternatives). [community]

Tesamorelin add-on debate: Some stack Tesa with CJC/IPA for “general GH + visceral fat” — others call dual GHRH redundant/expensive; lab monitoring talk rises with multi-GHRH exposure. [community]

Avoid redundant GHS overload: Stacking IPA + GHRP-2/6 + MK-677 simultaneously multiplies hunger/water/glucose noise with unclear extra benefit. [community]

Repair peptides (“Wolverine”): BPC-157 and/or TB-500 in injury-season recovery logs alongside GH-axis support — different mechanism (local repair talk vs systemic GH pulse). [community]

GLOW / copper-adjacent recovery stacks: GHK-Cu sometimes layered in wellness “repair + GH axis” narratives; ratios and evidence quality vary widely. [community]

TRT / men’s health context: Frequently layered on testosterone replacement in clinic and forum logs — sleep/recovery complement, not a testosterone replacement. [community]

GLP-1 era: Discussed for lean-mass/recovery support during tirzepatide/semaglutide cuts — evidence is lifestyle anecdote; watch protein intake and resistance training first. [community]

2026 reta/tirz adjacency: Lean-preservation talk next to GLP-1 cuts is louder; the practical fight is the fasted window, not a new mcg chart. [community]

A reaction can outweigh an earlier benefit. The restart account described rapid heartbeat, throat swelling, blurred vision and fainting after an initially positive course. The cause was not established. Throat swelling, breathing trouble or fainting warrant urgent medical evaluation; they are not ordinary adjustment symptoms to endure. My experience with cjc/ipamorelin (Personal report · Accessed 2026-09-30) · PCI Pharmacy CJC1295/IPAMORELIN medication guide (Official context · Accessed 2026-09-30)

Watch the sleep, fluid and glucose tradeoffs. Reports include insomnia, daytime lethargy, appetite increase, facial puffiness, ring tightness, tingling hands, headache, nausea, joint aches and injection-site reactions. The original discussion also flags fasting glucose/A1c concerns, particularly alongside MK-677. A benefit report does not rule out these problems. CJC-1295+Ipamorelin experience (Community discussion · Accessed 2026-09-30)

Purity and immune-response questions remain. FDA flags peptide-impurity and immunogenicity concerns for both compounds and serious CJC-associated reactions including increased heart rate. A flush cannot verify identity, strength or safety; lack of a flush cannot diagnose a fake product. FDA: compounding substances with significant safety risks (Official context · Accessed 2026-09-30) · Six weeks, IGF-1 barely increased: underdosed, fake or expected? (Community discussion · Accessed 2026-09-30)

Medical histories and tested sport change the stakes. The pharmacy guide flags pregnancy/nursing uncertainty and cancer-history review; these are cautions, not proof that the blend causes cancer. WADA lists CJC-1295 and ipamorelin as prohibited growth-hormone-releasing factors at all times. PCI Pharmacy CJC1295/IPAMORELIN medication guide (Official context · Accessed 2026-09-30) · WADA Prohibited List: growth-hormone-releasing factors (Official context · Accessed 2026-09-30)

Source context — My experience with cjc/ipamorelin: DAC form, component split, purity and clinical diagnosis not established. Amounts therefore omitted from no-DAC dose bands. Self-reported fainting cannot establish mechanism, frequency or confirmed anaphylaxis.

Source context — PCI Pharmacy CJC1295/IPAMORELIN medication guide: Commercial pharmacy guidance, not FDA-approved labeling or efficacy proof. Its efficacy language and administration/food instructions are not adopted. Used for specific cautions only.

Source context — CJC-1295+Ipamorelin experience: Author discloses AI translation/editing. Same text appeared in a PepAudit search lead and is not counted twice. Subreddit promotes an external guide; first-person authenticity, DAC status of OP and other stacks unverified. Route-switch anecdote is not a recommendation.

Source context — FDA: compounding substances with significant safety risks: Safety-risk summary, not a response-rate estimate or finding that a particular user's vial caused an immune reaction. IV clinical adverse events cannot become a blend event rate.

Source context — Six weeks, IGF-1 barely increased: underdosed, fake or expected?: Uses 'subject' wording under no-human-use rules; identity/species not independently verified. No lab document reviewed. Small change is neither proven nonresponse nor evidence of a fake vial. Moderator-removed and hidden replies not inspected.

Source context — WADA Prohibited List: growth-hormone-releasing factors: Sport eligibility context only; no medical efficacy, general criminal-law determination or drug-test clearance window.